文章摘要
张英,李中,李绿竹,等.马来酸吡咯替尼治疗人类表皮生长因子受体 2阳性晚期乳腺癌伴肝转移 1例[J].安徽医药,2021,25(2):394-396.
马来酸吡咯替尼治疗人类表皮生长因子受体 2阳性晚期乳腺癌伴肝转移 1例
Pyrrolidine maleate in the treatment of HER2 positive advanced breast cancer with liver metastasis:a case report
  
DOI:10.3969/j.issn.1009-6469.2021.02.044.
中文关键词: 乳腺肿瘤  受体,表皮生长因子  肝转移  马来酸吡咯替尼
英文关键词: Breast neoplasms  Receptor, epidermal growth factor  Liver metastasis  Pyrrolidine maleate
基金项目:
作者单位
张英 河北大学附属医院乳腺外科河北保定 017000 
李中 河北大学附属医院乳腺外科河北保定 017000 
李绿竹 河北大学附属医院乳腺外科河北保定 017000 
陈鹊汀 河北大学附属医院乳腺外科河北保定 017000 
摘要点击次数: 1671
全文下载次数: 475
中文摘要:
      目的探讨马来酸吡咯替尼治疗人类表皮生长因子受体 2(HER2)阳性晚期乳腺癌伴肝转移的临床疗效。方法选取 2017年 4月至 2019年 4月河北大学附属医院收治的 HER2阳性晚期乳腺癌病人 1例,先行多西他赛 +卡铂 +曲妥珠单抗(TCbH)方案 6个周期,后再行卡铂 +曲妥珠单抗( CbH)2个周期,病情进展(新发、转移)后再予以马来酸吡咯替尼治疗,经乳腺摄影、上腹部、胸部及头颅 CT平扫,后复查肝脏核磁评估治疗效果。结果病人 2018年 9月复查核磁显示肝 S7转移瘤变小, 2019年 4月复查核磁显示病灶无明显进展。结论马来酸吡咯替尼治疗 HER2阳性晚期乳腺癌伴肝转移可能使病人获益。
英文摘要:
      Objective To explore the clinical efficacy of pyrrolidine maleate in the treatment of human epithelial factor receptor-2 (HER2)-positive advanced breast cancer with liver metastases.Methods A patient with HER2-positive advanced breast cancer admitted to The Affiliated Hospital of Hebei University from April 2017 to April 2019 was selected as the study subject. The TCbH regimen(docetaxel + carboplatin + trastuzumab) was given for 6 cycles, followed by CbH (carboplatin + trastuzumab) for 2 cycles. After diseaseprogression (emergence, metastasis), the patient was treated with pyrrolidine maleate, and the efficacy was assessed by mammography,upper abdomen, chest and head CT scan, and magnetic resonance imaging (MRI) of the liver.Results In September 2018, the patient's MRI reexamination result of the liver showed that the liver S7 metastasis became smaller. In April 2019, MRI reexamination result showed no significant progression.Conclusion Pyrrolidine maleate may benefit patients with HER2-positive advanced breast cancer with liver metastases.
查看全文   查看/发表评论  下载PDF阅读器
关闭

分享按钮